Lynch Syndrome and Why Tumors Are Screened Universally

The short answer#

Every colorectal and endometrial tumor is worth testing for the fingerprint of Lynch syndrome, because waiting for a dramatic family history to appear misses most of the people who carry it. Lynch syndrome is the most common inherited cause of colorectal and endometrial cancer, yet the majority of carriers never learn they have it until a cancer forces the question. Universal, or reflex, screening flips the sequence: the pathology lab looks for a molecular clue in the tumor first, and that clue decides who should be steered toward inherited-cancer testing and counseling. The point is not to explain the cancer already on the slide. It is to uncover a heritable cause that reshapes follow-up for your patient and, through relatives, for family members who are still cancer-free.

Key points#

• Lynch syndrome causes roughly 3 to 5 percent of colorectal cancers, but most carriers are unaware of their diagnosis.
• Testing the tumor (not the patient's blood) for mismatch repair loss catches carriers that older family-history checklists would have skipped.
• The gene involved matters enormously: cancer risk runs from very high with MLH1 and MSH2 down to modest with PMS2.
• An abnormal tumor result is a triage signal, not a diagnosis; confirmatory germline testing and counseling still have to follow.

Why cast such a wide net#

The case for testing everyone rests on a mismatch between how common Lynch syndrome is and how rarely it gets recognized. The American College of Gastroenterology evidence review puts the population carrier frequency at roughly 1 in 279 people and estimates that fewer than 10 percent of people with Lynch syndrome in the United States know they have it. Those two numbers together are the whole argument. A condition that touches about 1 in 279 people, yet stays hidden in nine of ten who carry it, cannot be reliably found by screening only the patients with a textbook pedigree.

For years the field tried exactly that. Checklists such as the Amsterdam and Bethesda criteria asked clinicians to flag families with clusters of early-onset cancers and then send those patients for testing. The trouble is that plenty of carriers have small families, or families where the cancers simply have not surfaced yet, or where the reported history is incomplete. Reserving testing for the striking cases let a large share of carriers slip through. Universal tumor screening removes the judgment call at the front door: the tumor itself is tested regardless of what the family tree looks like.

The biology the test exploits#

Lynch syndrome comes from an inherited change in one of the DNA mismatch repair (MMR) genes, most often MLH1, MSH2, MSH6, or PMS2. A related route involves EPCAM deletions that switch off the neighboring MSH2 gene. Think of these genes as a spellchecker that runs while DNA is copied, catching and fixing the tiny slips that creep into repetitive stretches of the genome known as microsatellites. When one copy is inherited faulty and the second is lost in a cell, the spellchecker goes offline. Errors then accumulate, the microsatellites become unstable, and the affected MMR protein disappears from view under the microscope. That instability and that missing protein are precisely the signals the screening reads.

Two laboratory methods look for the same failure from different angles. Immunohistochemistry (IHC) stains the tumor for the four MMR proteins and shows which, if any, have gone missing. Microsatellite instability (MSI) testing measures the accumulated repeat errors directly. Major bodies, including the ACG and the National Comprehensive Cancer Network, recommend running one of these on essentially all colorectal and endometrial cancers rather than limiting it to patients who satisfy the older clinical checklists.

Why the specific gene changes everything#

Calling all of this by one name, Lynch syndrome, hides a wide spread of actual risk. The gene involved is not a footnote; it is the main determinant of how aggressive surveillance should be. The Prospective Lynch Syndrome Database, an international observational cohort summarized in GeneReviews, offers some of the clearest gene-specific and age-specific estimates available.

For colorectal cancer risk by around age 70, the database reports high figures for MLH1 (roughly 44 to 53 percent) and MSH2 (roughly 42 to 46 percent), a meaningfully lower range for MSH6 (roughly 12 to 20 percent), and the lowest of the group for PMS2 (on the order of 3 percent). Endometrial cancer follows a separate pattern in female carriers: substantial risk with MSH2 (around 46 percent), MSH6 (around 41 percent), and MLH1 (around 35 percent), and much lower risk with PMS2 (roughly 12 to 13 percent). For some women, an endometrial cancer is the first Lynch-associated tumor to appear, which is exactly why endometrial specimens are screened alongside colorectal ones.

The practical upshot is that a PMS2 result and an MLH1 result should not put your patient on the same surveillance plan. Knowing the gene lets you calibrate a colonoscopy interval, and the counseling about other cancers, to the real risk rather than applying one blunt protocol. Worth noting, some retrospective cohorts have estimated higher PMS2 risk than the prospective database, so these numbers are still being refined as more prospective data mature.

From an abnormal stain to a genetic answer#

A positive tumor test does not, on its own, mean a person has Lynch syndrome. Most MMR-deficient tumors are sporadic, arising from changes that happened in the tumor alone and were never inherited. This is where reflex algorithms do their real work. When IHC shows loss of MLH1, the standard next move is to test the tumor for a BRAF V600E mutation or for MLH1 promoter hypermethylation. Either finding marks the tumor as almost certainly sporadic, because BRAF V600E is common in methylated sporadic cancers and rare in inherited MLH1 disease. Tumors that lack that sporadic signature, or that instead show loss of MSH2, MSH6, or PMS2, are the ones referred onward for germline (inherited) genetic testing and counseling to confirm a heritable variant.

So the screening is best pictured as a funnel. Every eligible tumor enters at the top. The MMR-normal ones drop out. Among the MMR-deficient ones, the reflex tests filter out the sporadic cases. What remains is a much smaller group of people who genuinely warrant an inherited-cancer evaluation, plus their relatives, who can then pursue cascade testing.

Where the evidence is strong, and where it leaks#

The front of the funnel is on solid ground. Testing the tumor is a sensitive and cost-effective way to identify people who should be offered germline testing, and it finds carriers that criteria-based approaches would have missed. The weaker link is everything downstream of the abnormal result. A clinical-practice survey of inherited gastrointestinal cancer specialists, published in the Journal of Genetic Counseling, described how insurance, cost, and limited tumor tissue can stall the germline step, and how the referral chain to at-risk relatives thins out at every stage. An abnormal tumor test only pays off if your patient and their family actually complete the follow-through.

Two honest limits deserve stating plainly. First, screening is triage, not diagnosis; an abnormal MMR result needs confirmatory germline testing before you tell anyone they have Lynch syndrome. Second, the penetrance figures are population estimates drawn from studied cohorts, not personal predictions, and they keep being revised as prospective data accumulate. Seen this way, universal tumor screening is a system for surfacing candidates for a genetic evaluation, and you collect its value only when counseling, confirmation, and relative testing follow.